Table 5.
Patient selection criteria along with the resulting tumor profiles in each of the studies and the mean total lymph node harvests.
| Lead Author | Selection criteria employed | Tumor Size (cm) |
T Stage (% of total) |
T12:34 ratio | Conventionally Node Negative (%) | No of lymph nodes resected (range) | ||||
| Tis | T1 | T2 | T3 | T4 | ||||||
| Saha | None | ns | Data not given | ns | 37 | 16 (ns) | ||||
| Wiese | None | ns | 0 | 14 | 22 | 53 | 11 | 36:63 | 41 | 16 (ns) |
| Waters | None | ns | Data not given | ns | 27 | 12 (ns) | ||||
| Bilchik | Early stage primary only | ns | 0 | 26 | 24 | 50 | 50:50 | 35 | 15 (2–28) | |
| Paramo | No distant metastatic disease | ns | 0 | 12 | 7 | 81 | 0 | 7:93 | 29 | 10 (ns) |
| Wood | Clinically localized primary | ns | 0 | 19 | 29 | 44 | 8 | 48:52 | 47 | 15 (2–28) |
| Wood | Small early stage cancers only | 1.4 | 27 | 54 | 9 | 9 | 0 | 91:9 | 9 | 13 (2–20) |
| Saha | None | ns | Data not given | ns | 40 | 20 (ns) | ||||
| Esser | No nodal or distant metastases | ns | Data not given | ns | 19.4 | 15 (12–16) | ||||
| Bendavid | None | ns | Data not given | ns | 65 | ns | ||||
| Paramo | No distant metastatic disease | ns | Data not given | ns | 27 | 12 (ns) | ||||
| Wood | Clinically localized | ns | Data not given | ns | 26 | 15 (2–28) | ||||
| Bilchik | Clinically localized | ns | 0 | 25 | 23 | 46 | 6 | 48:52 | 43 | 15 (3–28) |
| Kitagawa | Only if curative surgery | ns | Data not given | 29:71 | 43 | 24 (ns) | ||||
| Feig | None | ns | 7 | 6 | 23 | 58 | 6 | 36:64 | 33 | 13 (4–46) |
| Broderick-Villa | No known distant metastases | ? | 6 | 8 | 20 | 62 | 4 | 34:66 | 43 | 8 (1–17) |
| Tsioulias | Clinically localized only | ns | Data not given | ns | 21 | 14 (2–21) | ||||
| Nastro | None | ns | Data not given | ns | ns | ns | ||||
| Bilchik | Early stage primary only | ns | 20 | 46 | 14 | 20 | 0 | 80:20 | 21 | 14 (2–21) |
| Cox | None | ns | 0 | 6 | 36 | 58 | 0 | 42:58 | 41 | 18 (4–33) |
| Bilchik | Early stage primary only | 3.6 | 14 | 12 | 17 | 53 | 5 | 42:58 | 36 | 14 (ns) |
| Turner | None | ns | 0 | 12 | 10 | 75 | 4 | 22:78 | 52 | 11 (1–42) |
| Trocha | No distant metastases | ns | 26 | 12 | 18 | 42 | 2 | 56:44 | 38 | 16 (ns) |
| Veihl | None | 4.2 | 0 | 6 | 9 | 71 | 12 | 15:83 | 48 | 21 (5–40) |
| Levine | No gross nodal disease | ns | Data not given | ns | ns | ns | ||||
| Saha | Tumor resectable & no metastases | ns | Data not given | ns | 42 | ns | ||||
| Dan | None | ns | 17 | 15 | 13 | 53 | 3 | ns | 43 | ns |
| Braat | No distant metastases, gross invasion or nodal disease | ns | 0 | 6 | 20 | 51 | 23 | 26:74 | 34 | 9 (1–23) |
| Bertoglio | Stage I and II & no enlarged nodes only | ns | Data not given | ns | 65 | 13 (6–18) | ||||
| Read | Surgery with curative intent only | ns | Data not given | ns | 29 | 14 (7–45) | ||||
| Patten | No nodal or distant metastases | ns | Data not given | 37:63 | 39 | 14 (ns) | ||||
| Bertagnolli | Stage I, II and III only | ns | 0 | 29 | 16 | 46 | 9 | 35:65 | 67 | 17 (ns) |
| Saha | None | ns | 19 | 14 | 11 | 53 | 4 | 43:57 | 33 | 12 (ns) |
| Saha | None | ns | 11 | 10 | 15 | 51 | 5 | 34:66 | 41 | 14 (ns) |
| Bembenek | Conventionally node negative patients only | ns | Data not given | ns | 100 | 26 (10–59) | ||||
| Codnignola | No liver metastases | ns | 0 | 2 | 21 | 63 | 14 | 23:77 | 36 | 21 (6–47) |
| Dahl | No nodal or distant metastases | ns | Data not given | 11:88 | 40 | 17 (4–35) | ||||
| Bilchik | Potentially curable cancer with no distant metastases only | 3.5 (0.2–10.5) | 0 | 17 | 15 | 65 | 3 | 32:68 | 29 | 15 (ns) |
| Tuech | No nodal or distant disease | ns | 0 | 6 | 9 | 85 | 0 | 10:90 | 36 | 20 (12–32) |
| Saha | None | ns | 15 | 11 | 16 | 52 | 5 | 42:58 | 50 | 15 (ns) |
| Kelder | No gross nodal or distant metastases | ns | 0 | 0 | 23 | 73 | 4 | 23:77 | 21 | 14 (ns) |
| Thomas | None | ns | Data not given | ? | 38 | ns | ||||
| Covarelli | None | ns | Data not given | ns | 35 | ns | ||||
| Kelder | No gross nodal or distant metastases | ns | 0 | 1 | 20 | 70 | 9 | 21:79 | 41 | 11 (ns) |
| Bianchi | No T4 or metastatic disease | ns | 36 | 4.5 | 9 | 45 | 5 | 50:50 | 73 | 22 (8–38) |
| Murawa | No gross nodal or distant metastases | ns | 0 | 15 | 20 | 63 | 2 | 37:63 | 41 | 20 (3–96) |
| Bembenek | None | ns | Data not given | ns | 69 | 20 (4–79) | ||||
| Sandrucci | Stage I or II only | ns | Data not given | 100:0 | 69 | 9 (ns) | ||||
| Tiffet | Excluded if primary unresectable. | ns | Data not given | 22:78 | 41 | 18 (4–37) | ||||
| Lim | No gross nodal or distant metastases | ns | 0 | 4 | 26 | 66 | 4 | 30:70 | 16 | 13(ns) |
| Kusano | None | ns | 0 | 15 | 73 | 12 | 88:12 | 77 | 13.5 (ns) | |
| Quadros | Potential curable cancer, no distant metastases | 8.3 | 0 | 0 | 14 | 54 | 31 | 14:86 | 46 | 19 (ns) |
The order and format is the same as in Table 3.